Featured Press Release:

FDA Advisory Committee finds Data support the claim that Spiriva® Handihaler® reduces COPD Exacerbations

- Advisory committee also reaffirms the product’s safety profile -

Ridgefield, CT, and New York, November 19, 2009 —The U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee voted 11 to 1 that clinical data included in a supplemental new drug application (sNDA) provide substantial and convincing evidence to support the claim that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) reduces exacerbations (worsening of symptoms) in patients with chronic obstructive pulmonary disease (COPD).